Psychotherapy Clinical Trial
Official title:
Mindfulness-Based Behavioural Group Therapy for Adult Attention Deficit Hyperactivity Disorder - Randomized Clinical Trial
The study is developed to validate a new short psychotherapeutic group treatment for adults with ADHD diagnosis. The participants will be treated in a monocentric, parallel group randomized superiority study - one group with the new treatment and one group with well established relaxing treatment.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | December 2022 |
Est. primary completion date | April 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - adult ADHD - written informed consent - stable medication for at least two weeks - sufficient knowledge of the German language Exclusion Criteria: - personality disorder - schizophrenia / psychotic disorders - bipolar disorder - acute suicidality - disease of the central nervous system - no other psychotherapeutic treatment at the time of the study - pregnancy - IQ below 70 Points |
Country | Name | City | State |
---|---|---|---|
Germany | Neuropsychiatric Center of Hamburg | Hamburg |
Lead Sponsor | Collaborator |
---|---|
Peter Tonn | Universitätsklinikum Hamburg-Eppendorf |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of Symptoms measured by the Connors ADHD Adult Rating Scale (CAARS) | The long version of the CAARS (Conner's Adult AD(H)D Rating Scales (Christiansen et al., 2012)) combines self-report and observer rating questionnaires to assess current AD(H)D symptoms in adulthood. This instrument consists of 66 items based on a 4-point Likert scale and four subscales: Inattention/ Memory Problems, Hyperactivity/ Restlessness, Impulsivity/ Emotional Lability and Problems with Self-Concept. With regard to the scientific quality criteria, Christiansen (2012) reports internal consistencies with a Cronbach's a of .74 to .95 and a test-retest reliability from .71 to .93, range min. 66 to max. 264 points. | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Measure of the quality of life of the participants measured by World Health Organization Quality of Life Questionnaire | Quality of life will be assessed by the short version of WHOQOL-BREF (World Health Organization Quality of Life Questionnaire (Group, 1998)). The questionnaire consists of 26 items that were extracted from the complete version consists of 100 items (WHOQOL-100) based on a 5-point Likert scale. For the German short version, Cronbach's alpha scores between .76 and .88 (Skevington, Lotfy, O'Connell, & Group, 2004). Range from 26 to 105 (min.-max). | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Changes of attention functioning measured by change detection task and trail making test A and B of the computer based test setting Psychology Experiment Building Language (PEBL) | The change detection task, modeled paradigm by Luck and Vogel, examines the visual working memory and covers sustained and selective attention. Patients will see a first pattern of differently colored squares for 300ms followed by a 1000ms pause and then a second pattern of squares. The task is then to determine whether the colors of every square are identical, will be repeated 120 times and takes approximately 12 minutes in total. Reaction times and the amount of mistakes made will then give information on the level of functioning. In addition, a TMT-A and B (Reitan, 1992) will be conducted. Patients will be asked to first connect numbers ranging from 1 to 30 in increasing order and then numbers from one to 15 and letters from A through O alphabetically alternating. Reaction times, times between clicks and the amount of correct and incorrect clicks will provide insight to the level of attentional functioning. Measurement of single individual scores, no qualified range described. | Measurement 1 at inclusion , Measurement 2 is 2 months after inclusion, measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Changes of mindfulness measured by Mindful Attention Awareness Scale | In order to assess mindfulness as well as the perception of the "here and now", the German version of the MAAS (Mindful Attention Awareness Scale (Brown & Ryan, 2003)) is used. In total, it consists of 15 items on a 6-point Likert scale. Since non-mindful behaviors are described, high scores mean a higher level of mindfulness. The internal consistency, represented by Cronbach's alpha, amounts a = .83 for the German version (Michalak, Heidenreich, Ströhle, & Nachtigall, 2008).Range form 15 to 90 points. | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Changes of acceptance, measured by Acceptance and Action Questionnaire | The FAH II Questionnaire (Acceptance and Action Questionnaire), the German version of AAQ (Acceptance and Action Questionnaire (Bond et al., 2011; Hoyer & Gloster, 2013)), aims to measure acceptance and psychological flexibility. The questionnaire consists of seven items, based on a 7-point Likert scale. Hoyer and Gloster found Cronbach's alpha between.84 and .97 and a test-retest reliability of rtt = .74 - .85 for the German version (2011). Range from 7 to 49 points. | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Affective state measured with the Patient Health Questionnaire PHQ-9 | The PHQ (Patient Health Questionnaire, (Gräfe, Zipfel, Herzog, & Löwe, 2004)) is used for psychodiagnostic screening and a possible change in patient depression. It is a self-assessment tool based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV (Saß & Association, 1998)) and includes modules on somatoform disorders, depressive disorders, anxiety disorders, and eating disorders, alcohol abuse, psychosocial functioning, stressors, critical life events and for participants to menstruation, pregnancy and childbirth. In total, it contains 78 items, which are based on a 2- to 5-point Likert scale depending on the module. For the depression scale of PHQ-D the internal consistency according to Cronbach's alpha is a = .88, for the somatization scale a = .79. Different subscales, no combined score, individual ranges and scores. | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Measuring of satisfaction and willingness to change with visual analogue scales | Visual analogue scales (VAS) with regard to satisfaction with mental health and the willingness to change are going to be evaluated.Range from 0 to 10 per scale, no combined scores. | Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention | |
Secondary | Measuring of five individual parameters during every of the single treatment session | Each time before and after the therapy sessions, five visual analogue scales are to be filled in, on which patients evaluate their current mood, stress, restlessness, trust in effectiveness of psychotherapy and their energy level. Range from 0 to 10 per scale, no combined scores. | Measurement before and after every treatment session, 2-6 weeks after inclusion date, every week for the 8 weeks treatment period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04356924 -
Psychological Treatment to Support the Consequences of Cognitive Impairment
|
N/A | |
Recruiting |
NCT05030285 -
Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment
|
N/A | |
Not yet recruiting |
NCT05863637 -
Intensive Short-Term Dynamic Psychotherapy (ISTDP) for Anxiety Diagnoses in a Primary Care Setting
|
N/A | |
Active, not recruiting |
NCT05018312 -
Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety
|
N/A | |
Not yet recruiting |
NCT06038747 -
Self-monitoring and Reflection's Impact on Psychotherapy Outcomes: A Trial Protocol.
|
N/A | |
Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
Not yet recruiting |
NCT03706001 -
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
|
N/A | |
Recruiting |
NCT05587517 -
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
|
Phase 2 | |
Completed |
NCT05385458 -
Acceptance and Commitment Therapy (ACT) Tele-Counselling
|
N/A | |
Not yet recruiting |
NCT06366685 -
Development and Initial Application of a Combined Exercise and Psychological Intervention Program for Patients After Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04950608 -
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
|
Phase 2 | |
Not yet recruiting |
NCT05613972 -
Brief Suicide & Trauma Therapy for Suicide Risk
|
N/A | |
Active, not recruiting |
NCT03692130 -
Treatment of Depression With Mindfulness, Acceptance and Commitment
|
N/A | |
Recruiting |
NCT05356611 -
Engage for Late-Life Depression and Comorbid Executive Dysfunction
|
N/A | |
Not yet recruiting |
NCT06347822 -
Increasing Access to Evidence-Based Care in Integrated Behavioral Health
|
N/A | |
Not yet recruiting |
NCT05317598 -
The Key Model Of Courtesy And Integrıty
|
N/A | |
Not yet recruiting |
NCT06353282 -
MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents
|
Phase 2 | |
Not yet recruiting |
NCT03813264 -
Optimizing Outcomes of Dynamic Psychotherapy by the MATRIX: A Preliminary Study
|
N/A | |
Completed |
NCT05289583 -
Impact of Therapeutic Alliance on Dropout in a Naturalistic Sample of Patients With Borderline Pathology Receiving Residential DBT
|
||
Completed |
NCT03937167 -
Benefits of Group Psychotherapy Programs in the Treatment of Obesity
|
N/A |